2019 China Health Industry Summit held in Guangdong on November 19

2019 China Health Industry Summit was held in Guangdong on November 19, and they are all concerned about In 2019, the medical and health industry is facing a complex situation On the one hand, the medical and pharmaceutical policies are intensively changed or newly issued, the first batch of purchases with volume, the new version of the medical insurance catalog adjustment, the publication of the auxiliary drug catalog in many places, and the cancellation of "drug proportion" Pharmaceutical enterprises highly dependent on policy guidance need to constantly adjust their corporate strategies to adapt; on the other hand, the "pharmaceutical technology innovation" speed up shift, innovative drugs have been approved and listed, vaccines enter the era of big product driven, innovative devices accelerate domestic substitution, new industry changes brought about by AI integration, and so on Market changes are changing with each passing day All of these make the market have different judgment on the future In this context, the "2019 Health Industry Summit" hosted by 21st century economic report will be held in Guangzhou on November 19 Decoding the key to the stable development of enterprises will be the direction of this summit In the current environment of frequent changes in market and policy, and declining growth of income and profit, social responsibility highlights the value of enterprises Moreover, the competition among enterprises is not only limited to cost, quality and brand, but also rises to the strategic level of corporate social responsibility and corporate goodwill Especially in the field of big health, which is related to people's livelihood, consumers pay more attention to product quality, corporate reputation and other brand goodwill China's big health industry has grown rapidly into a national strategic industry in recent years The development of the industry has been boosted by the policy reform, the continuous adjustment of supervision, technological progress and financial support As a big health industry observer and supervisor, 21st century economic report has always stressed that "fulfilling social responsibility is the behavior attitude that health industry must adhere to" Following the first social responsibility report of China's listed health care companies released last year, the 21st century Industrial Research Institute will release the social responsibility report of China's listed health care companies in the second year at this year's summit According to reports, "social responsibility report" takes seven major indicators such as economic performance and market performance, employee rights and interests, environmental protection, product quality and safety as evaluation dimensions, and scores each indicator of more than 300 listed pharmaceutical and health companies of a share and Hong Kong stock one by one It is hoped that after quantifying the social responsibility of medical and health enterprises, the whole industry can pay attention to fulfilling the social responsibility and promote the healthy and sustainable development of the industry The report points out that there are still some health enterprises with weak environmental awareness and low investment in environmental protection It is hoped that more and more health enterprises are willing to stand up and take relevant responsibilities At the summit, senior executives from Novartis group (China), China Resources 39, guangyuyuan, Jianke, Jinyu medicine, shengnuo and other companies will elaborate the help of social responsibility on the sustainable development of the industry and the company from the perspective of the company's years of operation As a new bright spot of China's economy, big health industry is a new industry with huge market potential More and more entrepreneurs and investors embrace big health care Since this year, the new policies of medical big health industry have emerged frequently, which has brought pain to the industry, but at the same time, it also promotes the pharmaceutical industry to develop orderly and return to the road of value At the same time, the integration of science and technology, innovation ideas and large-scale health industry is accelerating, and technology empowerment brings changes in the industry format and form Under the joint effect of technology, market, policy and investment, the medical big health industry has entered a high-speed growth period, with rapid development in the fields of health management, specialized medical treatment, health preservation, biomedicine, etc In view of the future growth path of the enterprise, senior executives from meinian health, guangyuyuan, Baiji Shenzhou, jiinga, Zhongkang information, Zhengda Tianqing, haixinhui, micro medicine, benchmark medical, gaotejia investment group, Dongfang Gaosheng and other enterprises at the summit shared relevant views from their respective perspectives In the previous interview, industry insiders said that in the era of data, everything connected will have a huge impact on the whole industry, and the strategy and path of the enterprise will be adjusted accordingly Of course, in addition to technology, the development path of enterprises is inseparable from the in-depth understanding of the market and policies Contact information Activity consultation: 020-87387325 Miss Li Media cooperation: 020-87387291 Miss Chen